Cello Health Communications strengthens its European offerings

Cello Health today announces the rebranding of its European communications offerings, iS Health Group and Cello Health Communications, Teddington, effective immediately. The objective of the rebrand is to align, expand and strengthen the European communications offering, enabling Cello Health Communications to offer enhanced value to clients through even closer collaboration and the delivery of creative, […]

More +

Who can you find at BIO?

From June 19-22, representatives from all three Cello Health capabilities will be in attendance at BIO International in San Diego. Our experts in early asset development and commercialization can be found at booth 410. Stop by to meet Jon, Suzann and Kathryn and discuss how Cello Health’s unique fusion of expertise utilizing strategists, scientists and […]

More +

Meet our Early Asset Development and Commercialization Experts

With over 30 years of healthcare experience, Jim specializes in working with ambitious companies that are seeking to develop forward looking, market informed strategies for both new and existing products. Throughout his career he has worked with companies of all sizes located around the world, and he has worked in-depth across all top therapeutic areas […]

More +

Cello Health exhibiting at BIO 2017

Cello Health are pleased to announce our presence at the BIO International Convention, June 19-22 in San Diego, CA, USA. We are pleased to have representatives from Communications, Consulting and Insight attending the congress. Stop by booth 410 to speak to one of our team about our capabilities and extensive experience in early asset development and […]

More +

Cello Health exhibiting at BioTrinity 2017

Cello Health is pleased to announce that we will be exhibiting at BioTrinity 2017, Europe’s leading Biopartnering and Investment Conference, to be held on 8-10 May at the Novotel London West. Find representatives from our capabilities at Booth #25 to discuss how we can help with any of your early asset development or commercialisation challenges. To schedule […]

More +